Chemomab Therapeutics (CMMB) Net Cash Flow (2017 - 2023)
Chemomab Therapeutics posted quarterly Net Cash Flow of $140000.0 for Q4 2023, down 94.96% year-on-year from $2.8 million in Q4 2022, and up 111.4% on a QoQ basis from -$1.2 million in Q3 2023.
Chemomab Therapeutics (CMMB) has 7 years of Net Cash Flow data on file, last reported at $140000.0 in Q4 2023.
- For the quarter ending Q4 2023, Net Cash Flow fell 94.96% year-over-year to $140000.0; the trailing twelve-month figure through Sep 2024 stood at $140000.0 (up 108.81% YoY), and the FY2025 full-year result was $1.4 million, up 144.92% from the prior year.
- Net Cash Flow for Q4 2023 stood at $140000.0, up from -$1.2 million in the prior quarter.
- Across five years, Net Cash Flow topped out at $46.5 million in Q1 2021 and bottomed at -$22.6 million in Q4 2021.
- The 5-year median for Net Cash Flow is -$1.3 million (2022), against an average of $357750.0.
- Peak annual rise in Net Cash Flow reached 3368.03% in 2021, while the deepest fall reached 2166.93% in 2021.
- A 5-year view of Net Cash Flow shows it stood at -$5.7 million in 2019, then surged by 82.43% to -$995000.0 in 2020, then tumbled by 2166.93% to -$22.6 million in 2021, then surged by 112.32% to $2.8 million in 2022, then sank by 94.96% to $140000.0 in 2023.
- The last three Net Cash Flow figures came in at $140000.0 (Q4 2023), -$1.2 million (Q3 2023), and -$10.4 million (Q2 2023), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 2.44 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 625.70 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -2.44 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 457.40 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | -152.20 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 60.68 Mn |
| 10 | Chemomab Therapeutics | 959.23 Mn | 948.86 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | 140,000.00 |
| Dec 31, 2023 | 140,000.00 |
| Sep 30, 2023 | -1.23 Mn |
| Sep 30, 2023 | -1.23 Mn |
| Jun 30, 2023 | -10.39 Mn |
| Jun 30, 2023 | -10.39 Mn |
| Mar 31, 2023 | 7.25 Mn |
| Mar 31, 2023 | 7.25 Mn |
| Dec 31, 2022 | 2.78 Mn |
| Dec 31, 2022 | 2.78 Mn |
| Sep 30, 2022 | 858,000.00 |
| Sep 30, 2022 | 858,000.00 |
| Jun 30, 2022 | -3.95 Mn |
| Jun 30, 2022 | -3.95 Mn |
| Mar 31, 2022 | -1.33 Mn |
| Mar 31, 2022 | -1.33 Mn |
| Dec 31, 2021 | -22.56 Mn |
| Dec 31, 2021 | -22.56 Mn |
| Sep 30, 2021 | -7.65 Mn |
| Sep 30, 2021 | -7.65 Mn |
| Jun 30, 2021 | -12.78 Mn |
| Jun 30, 2021 | -12.78 Mn |
| Mar 31, 2021 | 46.50 Mn |
| Mar 31, 2021 | 46.50 Mn |
| Dec 31, 2020 | -995,000.00 |
| Dec 31, 2020 | -995,000.00 |
| Sep 30, 2020 | -359,000.00 |
| Sep 30, 2020 | -359,000.00 |
| Jun 30, 2020 | 2.22 Mn |
| Jun 30, 2020 | 2.22 Mn |
| Mar 31, 2020 | -1.42 Mn |
| Mar 31, 2020 | -1.42 Mn |
| Dec 31, 2019 | -5.66 Mn |
| Dec 31, 2019 | -5.66 Mn |
| Sep 30, 2019 | -3.76 Mn |
| Sep 30, 2019 | -3.76 Mn |
| Jun 30, 2019 | -5.13 Mn |
| Jun 30, 2019 | -5.13 Mn |
| Mar 31, 2019 | 24.62 Mn |
| Mar 31, 2019 | 24.62 Mn |
| Dec 31, 2018 | -4.09 Mn |
| Dec 31, 2018 | -4.09 Mn |
| Sep 30, 2018 | -8.52 Mn |
| Sep 30, 2018 | -8.52 Mn |
| Jun 30, 2018 | 18.93 Mn |
| Jun 30, 2018 | 18.93 Mn |
| Mar 31, 2018 | -781,000.00 |
| Mar 31, 2018 | -781,000.00 |
| Dec 31, 2017 | -1.89 Mn |
| Dec 31, 2017 | -1.89 Mn |